• Mashup Score: 1
    Home - 8 month(s) ago

    In this live, interactive program, expert faculty will present and discuss the most recent data and clinical advances as well as provide expert perspectives on optimal clinical decision-making for three rare, complex hematologic disorders marked by dysfunction of the complement cascade: atypical hemolytic uremic syndrome (aHUS), paroxysmal nocturnal hemoglobinuria (PNH), and hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA). Clinical case vignettes will be highlighted

    Tweet Tweets with this article
    • READY FOR #ASH2023 ❓ Join our experts 📆 December 8 at ⏰ 3:30 PM PT. Learn how to accurately diagnose patients with specific #hematologic disorders. Limited seats available, click here now to register: https://t.co/YdxmSPuJQk #OncTwitter #Oncology #aHUS #PNH #HSCTTMA https://t.co/j4EYQRwg5y

  • Mashup Score: 0

    Home > PNH > FDA Accepts Application for Novel Treatment of Paroxysmal Nocturnal Hemoglobinuria The US Food and Drug Administration (FDA) has accepted a Biologics License Application (BLA) for crovalimab, a novel, investigational, anti-C5 recycling antibody developed to treat paroxysmal nocturnal hemoglobinuria (PNH). “This filing acceptance reinforces the value of crovalimab, which was engineered to be recy cled in the bloodstream, with the goal of offering a sustained response while reducing treatment

    Tweet Tweets with this article
    • The US Food and Drug Administration (FDA) has accepted a Biologics License Application (BLA) for crovalimab, a novel, investigational, anti-C5 recycling antibody developed to treat paroxysmal nocturnal hemoglobinuria (PNH). #hematology #PNH https://t.co/yIsht0IOZF https://t.co/JkCTn7Ohiu

  • Mashup Score: 0
    Home - 8 month(s) ago

    In this live, interactive program, expert faculty will present and discuss the most recent data and clinical advances as well as provide expert perspectives on optimal clinical decision-making for three rare, complex hematologic disorders marked by dysfunction of the complement cascade: atypical hemolytic uremic syndrome (aHUS), paroxysmal nocturnal hemoglobinuria (PNH), and hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA). Clinical case vignettes will be highlighted

    Tweet Tweets with this article
    • READY FOR #ASH2023 ❓ Join our experts 📆 December 8 at ⏰ 3:30 PM PT. Learn how to accurately diagnose patients with specific #hematologic disorders. Limited seats available, click here now to register: https://t.co/KzIZmM0RBm #OncTwitter #Oncology #aHUS #PNH #HSCTTMA https://t.co/I7p3C7FLSr